Isocitrate dehydrogenase 1 and 2 mutations in cancer: Alterations at a crossroads of cellular metabolism

Journal of the National Cancer Institute

Volumn 102, Issue 13, 2010, Pages 932-941

  Reitman, Zachary J ^a   Yan, Hai ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; ARGININE; GLUCOSE; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; UNCLASSIFIED DRUG; ALPHA-HYDROXYGLUTARATE; GLUTARIC ACID DERIVATIVE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE 2, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER GRADING; CELL METABOLISM; CODON; CRYSTAL STRUCTURE; ENZYME ACTIVITY; GLIOMA; HUMAN; HYPOXIA; KARYOTYPE; LIPID METABOLISM; LIPOGENESIS; MUTAGENESIS; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE; OXIDATIVE STRESS; OXYGEN SENSING; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; WORLD HEALTH ORGANIZATION; ANIMAL; ANOXIA; BRAIN TUMOR; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; GLIOBLASTOMA; METABOLISM; MUTATION; NEOPLASM; OLIGODENDROGLIOMA; TUMOR SUPPRESSOR GENE; ULTRASTRUCTURE; UPREGULATION;

ANIMALS; ANOXIA; ARGININE; BRAIN NEOPLASMS; CODON; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GLIOBLASTOMA; GLUCOSE; GLUTARATES; HUMANS; ISOCITRATE DEHYDROGENASE; MUTATION; NADP; NEOPLASMS; OLIGODENDROGLIOMA; ONCOGENES; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 77954697566     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq187     Document Type: Review

References (86)

1. Gabriel JL, Zervos PR, Plaut GW. Activity of purifed NAD-specifc isoci-trate dehydrogenase at modulator and substrate concentrations approximating conditions in mitochondria. Metabolism. 1986;35(7):661-667.
2. Jennings GT, Sechi S, Stevenson PM, Tuckey RC, Parmelee D, McAlister-Henn L. Cytosolic NADP(+)-dependent isocitrate dehydroge-nase. Isolation of rat cDNA and study of tissue-specifc and developmental expression of mRNA. J Biol Chem. 1994;269(37):23128-23134.
3. Nekrutenko A, Hillis DM, Patton JC, Bradley RD, Baker RJ. Cytosolic isocitrate dehydrogenase in humans, mice, and voles and phylogenetic analysis of the enzyme family. Mol Biol Evol. 1998;15(12):1674-1684.
4. Geisbrecht BV, Gould SJ. The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase. J Biol Chem. 1999;274(43):30527-30533.
5. Henke B, Girzalsky W, Berteaux-Lecellier V, Erdmann R. IDP3 encodes a peroxisomal NADP-dependent isocitrate dehydrogenase required for the beta-oxidation of unsaturated fatty acids. J Biol Chem. 1998;273(6):3702-3711.
6. Yoshihara T, Hamamoto T, Munakata R, Tajiri R, Ohsumi M, Yokota S. Localization of cytosolic NADP-dependent isocitrate dehydrogenase in the peroxisomes of rat liver cells: biochemical and immunocytochemical studies. J Histochem Cytochem. 2001;49(9):1123-1131.
7. Luo H, Shan X, Wu J. Expression of human mitochondrial NADP-dependent isocitrate dehydrogenase during lymphocyte activation. J Cell Biochem. 1996;60(4):495-507.
8. Dean AM, Lee MH, Koshland DE Jr. Phosphorylation inactivates Escherichia coli isocitrate dehydrogenase by preventing isocitrate binding. J Biol Chem. 1989;264(34):20482-20486.
9. Hurley JH, Thorsness PE, Ramalingam V, Helmers NH, Koshland DE Jr, Stroud RM. Structure of a bacterial enzyme regulated by phos-phorylation, isocitrate dehydrogenase. Proc Natl Acad Sci USA. 1989; 86(22):8635-8639.
10. Dean AM, Koshland DE Jr. Electrostatic and steric contributions to regulation at the active site of isocitrate dehydrogenase. Science. 1990; 249(4972):1044-1046.
11. Hurley JH, Dean AM, Sohl JL, Koshland DE Jr, Stroud RM. Regulation of an enzyme by phosphorylation at the active site. Science. 1990;249(4972): 1012-1016.
12. Hurley JH, Dean AM, Thorsness PE, Koshland DE Jr, Stroud RM. Regulation of isocitrate dehydrogenase by phosphorylation involves no long-range conformational change in the free enzyme. J Biol Chem. 1990; 265(7):3599-3602.
13. Dean AM, Koshland DE Jr. Kinetic mechanism of Escherichia coli isoci-trate dehydrogenase. Biochemistry. 1993;32(36):9302-9309.
14. Ceccarelli C, Grodsky NB, Ariyaratne N, Colman RF, Bahnson BJ. Crystal structure of porcine mitochondrial NADP+-dependent isocitrate dehydrogenase complexed with Mn2+ and isocitrate. Insights into the enzyme mechanism. J Biol Chem. 2002;277(45):43454-43462.
15. Xu X, Zhao J, Xu Z, et al. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J Biol Chem. 2004;279(32):33946-33957.
16. Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605-1612.
17. Winkler BS, DeSantis N, Solomon F. Multiple NADPH-producing pathways control glutathione (GSH) content in retina. Exp Eye Res. 1986; 43(5):829-847.
18. Haselbeck RJ, McAlister-Henn L. Function and expression of yeast mito-chondrial NAD-and NADP-specifc isocitrate dehydrogenases. J Biol Chem. 1993;268(16):12116-12122.
19. Lee SH, Jo SH, Lee SM, et al. Role of NADP+-dependent isocitrate de-hydrogenase (NADP+-ICDH) on cellular defence against oxidative injury by gamma-rays. Int J Radiat Biol. 2004;80(9):635-642.
20. Kim SY, Lee SM, Tak JK, Choi KS, Kwon TK, Park JW. Regulation of singlet oxygen-induced apoptosis by cytosolic NADP+-dependent isoci-trate dehydrogenase. Mol Cell Biochem. 2007;302(1-2):27-34.
21. Jo SH, Lee SH, Chun HS, et al. Cellular defense against UVB-induced phototoxicity by cytosolic NADP(+)-dependent isocitrate dehydrogenase. Biochem Biophys Res Commun. 2002;292(2):542-549.
22. Joseph JW, Jensen MV, Ilkayeva O, et al. The mitochondrial citrate/isoci-trate carrier plays a regulatory role in glucose-stimulated insulin secretion. J Biol Chem. 2006;281(47):35624-35632.
23. Hartong DT, Dange M, McGee TL, Berson EL, Dryja TP, Colman RF. Insights from retinitis pigmentosa into the roles of isocitrate dehydroge-nases in the Krebs cycle. Nat Genet. 2008;40(10):1230-1234.
24. Lee JH, Kim SY, Kil IS, Park JW. Regulation of ionizing radiation-induced apoptosis by mitochondrial NADP+-dependent isocitrate dehy-drogenase. J Biol Chem. 2007;282(18):13385-13394.
25. Shin AH, Kil IS, Yang ES, Huh TL, Yang CH, Park JW. Regulation of high glucose-induced apoptosis by mitochondrial NADP+-dependent isocitrate dehydrogenase. Biochem Biophys Res Commun. 2004;325(1): 32-38.
26. Kil IS, Kim SY, Lee SJ, Park JW. Small interfering RNA-mediated silencing of mitochondrial NADP+-dependent isocitrate dehydrogenase enhances the sensitivity of HeLa cells toward tumor necrosis factor-alpha and anticancer drugs. Free Radic Biol Med. 2007;43(8):1197-1207.
27. Shin SW, Kil IS, Park JW. Silencing of mitochondrial NADP+-dependent isocitrate dehydrogenase by small interfering RNA enhances heat shock-induced apoptosis. Biochem Biophys Res Commun. 2008;366(4):1012-1018.
28. Sazanov LA, Jackson JB. Proton-translocating transhydrogenase and NAD-and NADP-linked isocitrate dehydrogenases operate in a substrate cycle which contributes to fne regulation of the tricarboxylic acid cycle activity in mitochondria. FEBS Lett. 1994;344(2-3):109-116.
29. Comte B, Vincent G, Bouchard B, Benderdour M, Des Rosiers C. Reverse fux through cardiac NADP(+)-isocitrate dehydrogenase under normoxia and ischemia. Am J Physiol Heart Circ Physiol. 2002;283(4):H1505-H1514.
30. van Roermund CW, Hettema EH, Kal AJ, van den Berg M, Tabak HF, Wanders RJ. Peroxisomal beta-oxidation of polyunsaturated fatty acids in Saccharomyces cerevisiae: isocitrate dehydrogenase provides NADPH for reduction of double bonds at even positions. EMBO J. 1998;17(3): 677-687.
31. Minard KI, McAlister-Henn L. Dependence of peroxisomal beta-oxidation on cytosolic sources of NADPH. J Biol Chem. 1999;274(6):3402-3406.
32. Shechter I, Dai P, Huo L, Guan G. IDH1 gene transcription is sterol regulated and activated by SREBP-1a and SREBP-2 in human hepatoma HepG2 cells: evidence that IDH1 may regulate lipogenesis in hepatic cells. J Lipid Res. 2003;44(11):2169-2180.
33. Ronnebaum SM, Ilkayeva O, Burgess SC, et al. A pyruvate cycling pathway involving cytosolic NADP-dependent isocitrate dehydrogenase regulates glucose-stimulated insulin secretion. J Biol Chem. 2006;281(41): 30593-30602.
34. Koh HJ, Lee SM, Son BG, et al. Cytosolic NADP+-dependent isocitrate dehydrogenase plays a key role in lipid metabolism. J Biol Chem. 2004; 279(38):39968-39974.
35. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010; 17(3):225-234.
36. Mailloux RJ, Beriault R, Lemire J, et al. The tricarboxylic acid cycle, an ancient metabolic network with a novel twist. PLoS ONE. 2007;2(1):e690.
37. Nakamura H. Thioredoxin and its related molecules: update 2005. Antioxid Redox Signal. 2005;7(5-6):823-828.
38. Lee SM, Koh HJ, Park DC, Song BJ, Huh TL, Park JW. Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic Biol Med. 2002;32(11):1185-1196.
39. Lee SM, Park SY, Shin SW, Kil IS, Yang ES, Park JW. Silencing of cyto-solic NADP(+)-dependent isocitrate dehydrogenase by small interfering RNA enhances the sensitivity of HeLa cells toward staurosporine. Free Radic Res. 2009;43(2):165-173.
40. Kil IS, Lee YS, Bae YS, Huh TL, Park JW. Modulation of NADP(+)-dependent isocitrate dehydrogenase in aging. Redox Rep. 2004;9(5): 271-277.
41. Yang S, Liu T, Li S, et al. Comparative proteomic analysis of brains of naturally aging mice. Neuroscience. 2008;154(3):1107-1120.
42. Yang JH, Yang ES, Park JW. Inactivation of NADP+-dependent isocitrate dehydrogenase by lipid peroxidation products. Free Radic Res. 2004;38(3): 241-249.
43. Kim SY, Tak JK, Park JW. Inactivation of NADP(+)-dependent isocitrate dehydrogenase by singlet oxygen derived from photoactivated rose bengal. Biochimie. 2004;86(8):501-507.
44. Park SY, Lee SM, Shin SW, Park JW. Inactivation of mitochondrial NADP+-dependent isocitrate dehydrogenase by hypochlorous acid. Free Radic Res. 2008;42(5):467-473.
45. Lee SM, Huh TL, Park JW. Inactivation of NADP(+)-dependent isoci-trate dehydrogenase by reactive oxygen species. Biochimie. 2001;83(11-12): 1057-1065.
46. Yang ES, Richter C, Chun JS, Huh TL, Kang SS, Park JW. Inactivation of NADP(+)-dependent isocitrate dehydrogenase by nitric oxide. Free Radic Biol Med. 2002;33(7):927-937.
47. Yang ES, Lee JH, Park JW. Ethanol induces peroxynitrite-mediated tox-icity through inactivation of NADP+-dependent isocitrate dehydrogenase and superoxide dismutase. Biochimie. 2008;90(9):1316-1324.
48. Shin SW, Oh CJ, Kil IS, Park JW. Glutathionylation regulates cytosolic NADP+-dependent isocitrate dehydrogenase activity. Free Radic Res. 2009;43(4):409-416.
49. Lee JH, Yang ES, Park JW. Inactivation of NADP+-dependent isocitrate dehydrogenase by peroxynitrite. Implications for cytotoxicity and alcohol-induced liver injury. J Biol Chem. 2003;278(51):51360-51371.
50. Kil IS, Lee JH, Shin AH, Park JW. Glycation-induced inactivation of NADP(+)-dependent isocitrate dehydrogenase: implications for diabetes and aging. Free Radic Biol Med. 2004;37(11):1765-1778.
51. Batinic-Haberle I, Benov LT. An SOD mimic protects NADP+-dependent isocitrate dehydrogenase against oxidative inactivation. Free Radic Res. 2008;42(7):618-624.
52. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807-1812.
53. Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol. 2006;1:97-117.
54. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773.
55. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116(6):597-602.
56. Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but are rare in primary glioblastomas. Neuro Oncol. 2009;11(4):341-347.
57. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174(4):1149-1153.
58. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118(4):469-474.
59. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27(25):4150-4154.
60. Bleeker FE, Lamba S, Leenstra S, et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat. 2009;30(1):7-11.
61. Kang MR, Kim MS, Oh JE, et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer. 2009;125(2): 353-355.
62. Park SW, Chung NG, Han JY, et al. Absence of IDH2 codon 172 mutation in common human cancers. Int J Cancer. 2009;125(10):2485-2486.
63. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11): 1058-1066.
64. Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med. 2010;362(4):369-370.
65. Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010;207(2): 339-344.
66. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314(5797):268-274.
67. De Carli E, Wang X, Puget S. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(21):2248;author reply 2249.
68. Reitman Z, Yan H. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(21):2249;author reply 2249.
69. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009;15(19):6002-6007.
70. Watanabe T, Vital A, Nobusawa S, Kleihues P, Ohgaki H. Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathol. 2009;117(6):653-656.
71. Ohgaki H, Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci. 2009;15(19):6002-6007.
72. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classifcation of tumours of the central nervous system. Acta Neuropathol. 2007;114(2): 97-109.
73. Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 domi-nantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009;324(5924):261-265.
74. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739-744.
75. Jennings GT, Minard KI, McAlister-Henn L. Expression and mutagenesis of mammalian cytosolic NADP+-specifc isocitrate dehydrogenase. Biochemistry. 1997;36(44):13743-13747.
76. Soundar S, Danek BL, Colman RF. Identifcation by mutagenesis of argi-nines in the substrate binding site of the porcine NADP-dependent isoci-trate dehydrogenase. J Biol Chem. 2000;275(8):5606-5612.
77. Haliloglu G, Jobard F, Oguz KK, et al. L-2-hydroxyglutaric aciduria and brain tumors in children with mutations in the L2HGDH gene: neuroim-aging fndings. Neuropediatrics. 2008;39(2):119-122.
78. Kranendijk M, Struys EA, Gibson KM; et al. Evidence for genetic heterogeneity in D-2-hydroxyglutaric aciduria. Hum Mutat. 2009;31(3):279-283.
79. Struys EA, Gibson KM, Jakobs C. Novel insights into L-2-hydroxyglutaric aciduria: mass isotopomer studies reveal 2-oxoglutaric acid as the metabolic precursor of L-2-hydroxyglutaric acid. J Inherit Metab Dis. 2007; 30(5):690-693.
80. Reitman ZJ, Parsons DW, Yan H. IDH1 and IDH2: not your typical oncogenes. Cancer Cell. 2010;17(3):215-216.
81. Bleeker FE, Atai NA, Lamba S, et al. The prognostic IDH1 (R132) mutation is associated with reduced NADP (+)-dependent IDH activity in glioblastoma. Acta Neuropathol. 2010;119(4):487-494.
82. King A, Selak MA, Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene. 2006;25(34):4675-4682.
83. Frezza C, Tennant DA, Gottlieb E. IDH1 mutations in gliomas: when an enzyme loses its grip. Cancer Cell. 2010;17(1):7-9.
84. Ducray F, Marie Y, Sanson M. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(21):2248;author reply 2249.
85. Korshunov A, Meyer J, Capper D, et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocy-toma. Acta Neuropathol. 2009;118(3):401-405.
86. Thompson CB. Metabolic enzymes as oncogenes or tumor suppressors. N Engl J Med. 2009;360(8):813-815.